Drug Profile


Alternative Names: ALKS-29; ALKS-33/baclofen; Baclofen/ALKS-33

Latest Information Update: 26 Sep 2011

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Alkermes
  • Class Aminobutyric acids; Drug withdrawal therapies; Small molecules
  • Mechanism of Action GABA B receptor agonists; Opioid mu receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Alcoholism

Most Recent Events

  • 05 Dec 2008 Alkermes initiates a Phase-I trial for Alcoholism in the USA
  • 31 Jul 2008 Phase I/II development is ongoing in the US
  • 06 Jul 2007 Results from a phaseI/II clinical trial in patients with alcoholism added to the adverse events and Drug Withdrawal therapeutic trials sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top